Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase EARLY_PHASE1 2Phase 3 2Phase 2/3 2Phase NA 1Phase 4 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Advanced Cancer 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Mirtazapine × Clear all
NCT03254173 2020-02-05

MCACS100

Kasr El Aini Hospital

Phase 2/3 Completed
120 enrolled

Advanced Cancer

NCT01598584 2015-09-28

Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2/3 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡